New drugs: sitagliptin phosphate, telbivudine, and panitumumab.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D009705:Nucleosides / Q000627:therapeutic use*; D000077544:Panitumumab; D011719:Pyrazines / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D014230:Triazoles / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D007004:Hypoglycemic Agents; D009705:Nucleosides; D011719:Pyrazines; D011744:Pyrimidinones; D014230:Triazoles; D000077712:Telbivudine; D000077544:Panitumumab; D000068900:Sitagliptin Phosphate; D013936:Thymidine